These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6533950)

  • 1. Bound and circulating heparin in an ECMO system thrombogenicity versus functionality.
    Roohk HV; Calabrese D; Sanematsu L; Castillo G; Cottonaro CN
    Trans Am Soc Artif Intern Organs; 1984; 30():639-43. PubMed ID: 6533950
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of bound heparin in prolonged extracorporeal membrane oxygenation.
    Toomasian JM; Zwischenberger JB; Oram AD; DeSmet GM; Bartlett RH
    Trans Am Soc Artif Intern Organs; 1984; 30():133-6. PubMed ID: 6533877
    [No Abstract]   [Full Text] [Related]  

  • 3. Thrombogenicity is not reduced when heparin and phospholipid bonded circuits are used in a rabbit model of extracorporeal circulation.
    Meinhardt JP; Annich GM; Miskulin J; Kawai T; Ashton BA; Bartlett RH
    ASAIO J; 2003; 49(4):395-400. PubMed ID: 12918580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of thrombosis in extracorporeal circulation: variations of anticoagulation.
    Toomasian JM; Helmer GA; Zeme MI; Oltean JN; Oran AD; Bartlett RH
    Trans Am Soc Artif Intern Organs; 1983; 29():206-9. PubMed ID: 6673231
    [No Abstract]   [Full Text] [Related]  

  • 5. Extracorporeal circulation: in vivo and in vitro analysis of complement activation by heparin-bonded surfaces.
    Kirschfink M; Kovacs B; Mottaghy K
    Circ Shock; 1993 Jul; 40(3):221-6. PubMed ID: 8348684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-coated versus non-coated surfaces for extracorporeal circulation.
    Mottaghy K; Oedekoven B; Pöppel K; Kovacs B; Kirschfink M; Bruchmüller K; Kashefi A; Geisen C
    Int J Artif Organs; 1991 Nov; 14(11):721-8. PubMed ID: 1757160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New surface treatments to prevent thrombosis during extracorporeal circulation.
    Splittgerber FH; Whittlesey GC; Klein MD
    Trans Am Soc Artif Intern Organs; 1985; 31():474-8. PubMed ID: 3837492
    [No Abstract]   [Full Text] [Related]  

  • 8. Thrombogenicity of heparin and non-heparin bound arterial prostheses: an in vitro evaluation.
    Mohamed MS; Mukherjee M; Kakkar VV
    J R Coll Surg Edinb; 1998 Jun; 43(3):155-7. PubMed ID: 9654873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Activation of blood coagulation in extracorporeal circulation].
    Nowak G
    Wien Klin Wochenschr; 1996; 108 Suppl 1():9-14. PubMed ID: 8686324
    [No Abstract]   [Full Text] [Related]  

  • 10. Cross-linked heparin binding of a membrane oxygenator system.
    Eberle JW; Manton JR; Meals CR; Whitley DE; Rea WJ
    J Biomed Mater Res; 1973 Mar; 7(2):145-53. PubMed ID: 4703757
    [No Abstract]   [Full Text] [Related]  

  • 11. A new nonthrombogenic surface.
    Cottonaro CN; Roohk HV; Bartlett RH; Servas FM; Sperling DR
    Trans Am Soc Artif Intern Organs; 1982; 28():478-81. PubMed ID: 7164285
    [No Abstract]   [Full Text] [Related]  

  • 12. Prolonged circulatory assistance in awake neonatal lambs.
    Melrose DG; Singh MP
    J Thorac Cardiovasc Surg; 1974 Apr; 67(4):584-9. PubMed ID: 4818534
    [No Abstract]   [Full Text] [Related]  

  • 13. Bulk-heparinized catheters do not generate fibrinopeptide A in an ex-vivo test in dogs.
    Eloy R; Pusinéri C; Baguet J; Paul J; Serafini S
    Life Support Syst; 1983; 1 Suppl 1():247-50. PubMed ID: 6336421
    [No Abstract]   [Full Text] [Related]  

  • 14. Heparin free long-term extracorporeal circulation using bioactive surfaces.
    Mottaghy K; Oedekoven B; Pöppel K; Bruchmüller K; Kovacs B; Spahn A; Geisen C
    ASAIO Trans; 1989; 35(3):635-7. PubMed ID: 2512973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter: Silicone membrane oxygenator.
    Drinker PA; Bartlett RH
    J Thorac Cardiovasc Surg; 1974 Dec; 68(6):976. PubMed ID: 4213862
    [No Abstract]   [Full Text] [Related]  

  • 16. [The development of research on membrane oxgenator application].
    Wang L; Chen H; Wang K
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2007 Feb; 24(1):240-4. PubMed ID: 17333931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior blood compatibility of silicone rubber free of silica filler in the membrane lung.
    Kolobow T; Stool EW; Weathersby PK; Pierce J; Hayano F; Suaudeau J
    Trans Am Soc Artif Intern Organs; 1974; 20A():269-76. PubMed ID: 4450347
    [No Abstract]   [Full Text] [Related]  

  • 18. Biologically active heparin coating in medical devices.
    Olsson P; Larm O
    Int J Artif Organs; 1991 Aug; 14(8):453-6. PubMed ID: 1937934
    [No Abstract]   [Full Text] [Related]  

  • 19. Development and hemocompatibility testing of nitric oxide releasing polymers using a rabbit model of thrombogenicity.
    Major TC; Handa H; Annich GM; Bartlett RH
    J Biomater Appl; 2014 Oct; 29(4):479-501. PubMed ID: 24934500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Scanning electron microscopy studies of membrane surfaces for the establishment of a heparin-independent extracoporeal circulation system for long-term perfusion in pulmonary and cardiac insufficiency].
    Rosenbauer KA; Herzer JA; Jansen B; Falke K
    Verh Anat Ges; 1977; (71 Pt 2):823-30. PubMed ID: 610179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.